CO2021003530A2 - Conjugados de interleuquina 10 y usos de los mismos - Google Patents

Conjugados de interleuquina 10 y usos de los mismos

Info

Publication number
CO2021003530A2
CO2021003530A2 CONC2021/0003530A CO2021003530A CO2021003530A2 CO 2021003530 A2 CO2021003530 A2 CO 2021003530A2 CO 2021003530 A CO2021003530 A CO 2021003530A CO 2021003530 A2 CO2021003530 A2 CO 2021003530A2
Authority
CO
Colombia
Prior art keywords
conjugates
interleukin
kits
indications
treatment
Prior art date
Application number
CONC2021/0003530A
Other languages
English (en)
Inventor
Carolina E Caffaro
Jerod Ptacin
Marcos Milla
Original Assignee
Synthorx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synthorx Inc filed Critical Synthorx Inc
Publication of CO2021003530A2 publication Critical patent/CO2021003530A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5428—IL-10
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Abstract

Conjugados de interleuquina 10 y sus usos en el tratamiento de una o más indicaciones. Composiciones farmacéuticas y kits que comprenden uno o más de los conjugados de IL-10.
CONC2021/0003530A 2018-11-08 2021-03-18 Conjugados de interleuquina 10 y usos de los mismos CO2021003530A2 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862757690P 2018-11-08 2018-11-08
US201962911036P 2019-10-04 2019-10-04
PCT/US2019/060261 WO2020097325A1 (en) 2018-11-08 2019-11-07 Interleukin 10 conjugates and uses thereof

Publications (1)

Publication Number Publication Date
CO2021003530A2 true CO2021003530A2 (es) 2021-04-19

Family

ID=70612119

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2021/0003530A CO2021003530A2 (es) 2018-11-08 2021-03-18 Conjugados de interleuquina 10 y usos de los mismos

Country Status (16)

Country Link
US (1) US20210338829A1 (es)
EP (1) EP3876973A4 (es)
JP (1) JP2022506531A (es)
KR (1) KR20210091170A (es)
CN (1) CN113260374A (es)
AU (1) AU2019376076A1 (es)
BR (1) BR112021005401A2 (es)
CA (1) CA3117572A1 (es)
CO (1) CO2021003530A2 (es)
IL (1) IL282736A (es)
MA (1) MA54195A (es)
MX (1) MX2021005293A (es)
PH (1) PH12021550611A1 (es)
SG (1) SG11202102930YA (es)
TW (1) TW202031284A (es)
WO (1) WO2020097325A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200181220A1 (en) 2017-08-03 2020-06-11 Synthorx, Inc. Cytokine conjugates for the treatment of proliferative and infectious diseases
CN112004547A (zh) 2018-02-26 2020-11-27 新索思股份有限公司 Il-15缀合物及其用途
CN114949240A (zh) 2019-02-06 2022-08-30 新索思股份有限公司 Il-2缀合物及其使用方法
CH716227B1 (it) * 2020-04-16 2020-11-30 Contrad Swiss Sa Composizione in gel per applicazione topica per la riduzione dell'infiammazione locale.
WO2022125712A1 (en) * 2020-12-09 2022-06-16 Asher Biotherapeutics, Inc. Fusions of mutant interleukin-10 polypeptides with antigen binding molecules for modulating immune cell function
CN112618699A (zh) * 2020-12-31 2021-04-09 深圳先进技术研究院 一种能够提供治疗有效量的白介素10的试剂及其抗肿瘤应用
KR20240024235A (ko) * 2021-07-29 2024-02-23 노보코덱스 바이오파마슈티컬즈 컴퍼니 리미티드 비천연 아미노산, 및 이의 용도, 이를 함유하는 재조합 단백질, 및 재조합 단백질 컨주게이트

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004044006A1 (en) * 2002-11-14 2004-05-27 Maxygen, Inc. Conjugates of interleukin-10 and polymers
WO2004089421A2 (en) * 2003-03-31 2004-10-21 Xencor, Inc Methods for rational pegylation of proteins
WO2013130913A1 (en) * 2012-02-29 2013-09-06 Ambrx, Inc. Interleukin-10 polypeptide conjugates and their uses
CA2914837A1 (en) * 2013-06-17 2014-12-24 Armo Biosciences, Inc. Method for assessing protein identity and stability
AU2016312510A1 (en) * 2015-08-25 2018-03-08 Armo Biosciences, Inc. Methods of using Interleukin-10 for treating diseases and disorders
CN113366015A (zh) * 2018-10-19 2021-09-07 Ambrx公司 白细胞介素-10多肽缀合物、其二聚体及其用途

Also Published As

Publication number Publication date
KR20210091170A (ko) 2021-07-21
EP3876973A4 (en) 2022-08-03
TW202031284A (zh) 2020-09-01
SG11202102930YA (en) 2021-04-29
WO2020097325A1 (en) 2020-05-14
BR112021005401A2 (pt) 2021-06-29
MX2021005293A (es) 2021-06-23
JP2022506531A (ja) 2022-01-17
AU2019376076A1 (en) 2021-04-15
EP3876973A1 (en) 2021-09-15
US20210338829A1 (en) 2021-11-04
PH12021550611A1 (en) 2021-10-04
MA54195A (fr) 2022-02-16
CA3117572A1 (en) 2020-05-14
CN113260374A (zh) 2021-08-13
IL282736A (en) 2021-06-30

Similar Documents

Publication Publication Date Title
CO2020010303A2 (es) Conjugados de il-15, y sus usos
CO2021003530A2 (es) Conjugados de interleuquina 10 y usos de los mismos
CO2020001823A2 (es) Conjugados de citoquina para el tratamiento de enfermedades autoinmunes
CO2021009695A2 (es) Conjugados de il-2 y métodos de uso de este
CO2021001912A2 (es) Composiciones anti-cd112r y métodos
CL2019001874A1 (es) Inhibidores de tgfß1 isoforma-específicos contexto-permisivos y uso de los mismos.
CL2020000075A1 (es) Carboxamidas como moduladores de los canales de sodio.
CL2019000793A1 (es) Moduladores de calpaínas y usos terapéuticos de los mismos.
DOP2019000005A (es) 3-metil pirazinas 2,5-disustituidas y 3-metil pirazinas 2,5,6-trisustituidas como inhibidores alostéricos de shp2
DK3676316T3 (da) Flydende sammensætning omfattende biologiske enheder og anvendelser deraf
CL2016001364A1 (es) Moduladores de ror gamma (rory)
CL2016001609A1 (es) Composiciones farmacéuticas que comprenden azd9291.
CO2022001210A2 (es) Conjugados de il-2 y métodos de uso para tratar enfermedades autoinmunes
UY37098A (es) Moduladores de ror-gamma
CL2019000729A1 (es) Proteínas de unión recombinantes y sus usos.
CL2016002223A1 (es) Microorganismo recombinante que expresa análogos de avermectina y uso de los mismos.
CO2022003742A2 (es) Conjugados de interleuquina 10 y sus usos
CL2016001746A1 (es) Derivados de hidroxi formamida y sus usos
CO2022001050A2 (es) Novedosos conjugados de il–15 y sus usos
CL2018001913A1 (es) Derivados de 3-(carboxietil)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano
UY37669A (es) Conjugados de fármaco-anticuerpo (adc) anti-prlr y usos de los mismos
CL2020000056A1 (es) Nuevos derivados de xantina sustituidos.
BR112021011124A2 (pt) Anelossomos e métodos de uso
CL2022003194A1 (es) Composiciones farmacéuticas inyectables y usos de las mismas
CO2018011420A2 (es) Formulaciones líquidas de fosfaplatino